Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathias Bressel

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
BMC Cancer|October 25, 2018
TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK IIShankar Siva, Brent Chesson, Mathias Bressel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL StudyCristian Udovicich, Mathias Bressel, Jamil Manji, et al.
Blood Advances|December 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphomaSasanka M Handunnetti, Amit Khot, Piers Blombery, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2023
Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary OligometastasesShankar Siva, Pitchaya Sakyanun, Tao Mai, et al.
European Urology|December 26, 2021
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT TrialShankar Siva, Mathias Bressel, Simon T Wood, et al.
The Lancet. Oncology|May 17, 2026
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trialsShankar Siva, Muhammad Ali, Nicholas Hardcastle, et al.
Blood|April 25, 2024
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissionsSasanka M Handunnetti, Mary Ann Anderson, Kate Burbury, et al.
JAMA Oncology|August 29, 2021
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical TrialShankar Siva, Mathias Bressel, Tao Mai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2018
Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 TrialSandro Virgilio Porceddu, Mathias Bressel, Michael Geoffrey Poulsen, et al.
The Lancet. Oncology|February 29, 2024
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trialShankar Siva, Mathias Bressel, Mark Sidhom, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
BMC Cancer|October 25, 2018
TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK IIShankar Siva, Brent Chesson, Mathias Bressel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL StudyCristian Udovicich, Mathias Bressel, Jamil Manji, et al.
Blood Advances|December 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphomaSasanka M Handunnetti, Amit Khot, Piers Blombery, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2023
Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary OligometastasesShankar Siva, Pitchaya Sakyanun, Tao Mai, et al.
European Urology|December 26, 2021
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT TrialShankar Siva, Mathias Bressel, Simon T Wood, et al.
The Lancet. Oncology|May 17, 2026
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trialsShankar Siva, Muhammad Ali, Nicholas Hardcastle, et al.
Blood|April 25, 2024
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissionsSasanka M Handunnetti, Mary Ann Anderson, Kate Burbury, et al.
JAMA Oncology|August 29, 2021
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical TrialShankar Siva, Mathias Bressel, Tao Mai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2018
Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 TrialSandro Virgilio Porceddu, Mathias Bressel, Michael Geoffrey Poulsen, et al.
The Lancet. Oncology|February 29, 2024
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trialShankar Siva, Mathias Bressel, Mark Sidhom, et al.
Pageof 14